147 related articles for article (PubMed ID: 38229454)
21. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
[TBL] [Abstract][Full Text] [Related]
22. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
23. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
24. Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.
Hegedus B; Hughes FW; Garbow JR; Gianino S; Banerjee D; Kim K; Ellisman MH; Brantley MA; Gutmann DH
J Neuropathol Exp Neurol; 2009 May; 68(5):542-51. PubMed ID: 19525901
[TBL] [Abstract][Full Text] [Related]
25. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
27. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
28. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
29. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
30. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
31. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
32. Optic pathway glioma and endocrine disorders in patients with and without NF1.
Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
[TBL] [Abstract][Full Text] [Related]
33. NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.
Lobón-Iglesias MJ; Laurendeau I; Guerrini-Rousseau L; Tauziède-Espariat A; Briand-Suleau A; Varlet P; Vidaud D; Vidaud M; Brugieres L; Grill J; Pasmant E
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i98-i106. PubMed ID: 32642735
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
[TBL] [Abstract][Full Text] [Related]
35. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
36. Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas.
Gu S; Glaug N; Cnaan A; Packer RJ; Avery RA
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1402-8. PubMed ID: 24519429
[TBL] [Abstract][Full Text] [Related]
37. Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1.
Zeid JL
Front Surg; 2022; 9():908573. PubMed ID: 36117804
[TBL] [Abstract][Full Text] [Related]
38. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
39. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
40. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
